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Background
Long-term sedation with midazolam or propofol in 
intensive care units (ICUs) has serious adverse eﬀ ects. 
Dexmedetomidine, an alpha-2 agonist available for ICU 
sedation, may reduce the duration of mechanical venti-
lation and enhance patient comfort.
Methods
Objective: Th e objective was to determine the eﬃ  cacy of 
dexmedetomidine versus midazolam or propofol (pre-
ferred usual care) in maintaining sedation, reducing 
duration of mechanical ventilation, and improving 
patients’ interaction with nursing care.
Design: Two phase 3 multicenter, randomized, double-
blind trials were conducted.
Setting: Th e MIDEX (Midazolam vs. Dexmedetomidine) 
trial compared midazolam with dexmedetomidine in 
ICUs of 44  centers in nine European countries. Th e 
PRODEX (Propofol vs. Dexmedetomidine) trial com pared 
propofol with dexmedetomidine in 31  centers in six 
Euro pean countries and two centers in Russia.
Subjects: Th e subjects were adult ICU patients who were 
receiving mechanical ventilation and who needed light to 
moderate sedation for more than 24 hours.
Intervention: After enrollment, 251 and 249 subjects were 
randomly assigned midazolam and dexmedetomidine, 
respectively, in the MIDEX trial, and 247 and 251 subjects 
were randomly assigned propofol and dexmedetomidine, 
respectively, in the PRODEX trial. Sedation with dex-
medetomidine, midazolam, or propofol; daily sedation 
stops; and spontaneous breathing trials were employed.
Outcomes: For each trial, investigators tested whether 
dexmedetomidine was noninferior to control with 
respect to proportion of time at target sedation level 
(measured by Richmond Agitation Sedation Scale) and 
superior to control with respect to duration of 
mechanical venti lation. Secondary end points were the 
ability of the patient to communicate pain (measured by 
using a visual analogue scale [VAS]) and length of ICU 
stay. Time at target sedation was analyzed in per-protocol 
(midazolam, n = 233, versus dexmedetomidine, n = 227; 
pro pofol, n  =  214, versus dexmedetomidine, n  =  223) 
population.
Results
Dexmedetomidine/midazolam ratio in time at target 
sedation was 1.07 (95% conﬁ dence interval (CI) 0.97 to 
1.18), and dexmedetomidine/propofol ratio in time at 
target sedation was 1.00 (95% CI 0.92 to 1.08). Median 
duration of mechanical ventilation appeared shorter with 
dexmedetomidine (123  hours, interquartile range (IQR) 
67 to 337) versus midazolam (164 hours, IQR 92 to 380; 
P = 0.03) but not with dexmedetomidine (97 hours, IQR 
45 to 257) versus propofol (118  hours, IQR 48 to 327; 
P  =  0.24). Patient interaction (measured by using VAS) 
was improved with dexmedetomidine (estimated score 
diﬀ erence versus midazolam 19.7, 95% CI 15.2 to 24.2; 
P  <0.001; and versus propofol 11.2, 95% CI 6.4 to 15.9; 
P  <0.001). Lengths of ICU and hospital stays and 
mortality rates were similar. Dexmedetomidine versus 
midazolam patients had more hypotension (51/247 
[20.6%] versus 29/250 [11.6%]; P = 0.007) and bradycardia 
(35/247 [14.2%] versus 13/250 [5.2%]; P <0.001).
Conclusions
Among ICU patients receiving prolonged mechanical 
ventilation, dexmedetomidine was not inferior to mida-
zo lam and propofol in maintaining light to moderate 
sedation. Dexmedetomidine reduced duration of mech a-
ni cal ventilation compared with midazolam and improved 
the ability of patients to communicate pain compared 
with midazolam and propofol. Greater numbers of 
adverse eﬀ ects were associated with dexmedetomidine.© 2010 BioMed Central Ltd
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Commentary
Sedation is commonly used in the intensive care unit 
(ICU) to reduce patient discomfort, improve tolerance 
with mechanical ventilation, prevent accidental device 
removal, and reduce metabolic demands during respi ra-
tory and hemodynamic instability [1,2]. Continuous and 
deep sedation have been associated with increased risk of 
delirium, longer duration of mechanical ventilation, 
increased length of ICU and hospital stays, and long-
term risk of neurocognitive impairment, post-traumatic 
stress disorder, and mortality [3-7]. Sedation interruption 
and protocolized sedation have been associated with 
decreased length of ICU stay and reduced duration of 
mechanical ventilation [4,5]. Whether combining seda-
tion interruption and protocolized sedation improves 
outcome is controversial. Whereas some studies show a 
beneﬁ t [6], others show no diﬀ erence [8].
Commonly used ﬁ rst-line sedative medications, 
including propofol and midazolam, and less commonly 
used medications, such as lorazepam, have many side 
eﬀ ects. Th ere exists wide intra- and inter-individual varia-
bility [9], resulting in unpredictable drug accumu lation 
with benzodiazepines [10]. Lorazepam is asso ciated with 
propylene glycol-related acidosis and nephro toxicity. 
Propofol causes hypertriglyceridemia, pancreatitis, and 
propofol-related infusion syndrome [11,12]. Dexmedeto-
mi dine is a potent alpha-2 adrenoceptor agonist with an 
aﬃ  nity for the alpha-2 adrenoceptor that is eight times 
higher than that of clonidine [13]. Prior data suggest that 
dexmedetomidine reduced duration of mechanical venti-
lation and resulted in earlier extubation [14,15]. In 
critically ill patients, use of dexmedetomidine has been 
associated with lower risk of delirium and coma com-
pared with propofol, lorazepam, and midzolam [15,16]. 
However, safety and eﬃ  cacy of prolonged dexmedeto-
midine infusion in the ICU have not been evaluated.
Th e PRODEX (Propofol vs. Dexmedetomidine) and 
MIDEX (Midazolam vs. Dexmedetomidine) trials attemp-
ted to answer this question with higher doses of dex-
medetomidine for longer duration when compared with 
propofol and midazolam in mechanically ventilated 
patients. Both studies provide important clinical evi dence 
that dexmedetomidine is an eﬀ ective sedative agent 
compared with propofol and midazolam. Use of dex mede-
tomidine is associated with easier communication with 
patients, better assessment of pain (from the perspective 
of the caregiver), reduced delirium, and decreased time to 
extubation as compared with propofol. However, this 
ﬁ nding did not translate into reduction of length of ICU or 
hospital stay. Among the strengths of the study are that it 
was a well-conducted, large, multicenter, double-blind, 
randomized controlled study. Th e trial employed frequent 
sedation assessment, daily sedation stops, and a double-
dummy design to reduce the risk of bias.
Several important limitations to the study deserve 
further consideration. Th e weaning from mechanical 
ventilation and criteria for extubation were not s tandard-
ized. Spontaneous breath ing trials were performed in 
only about half of the sedation stops, as compared with 
approximately 60% of those screened in the Awakening 
and Breathing Con trolled trial [6]. Whereas the incidence 
of neurocognitive disorders, including delirium, anxiety, 
and agitation, was evaluated throughout the study, the 
long-term neuro cognitive and functional outcomes with 
dexmedetomi dine have not been examined. Sedation was 
assessed from the caregivers’ perspective only, and future 
studies should include the patients’ perspective of quality 
of sedation. Also, this study included only patients with 
light to moderate sedation; thus, these ﬁ ndings may not 
be applicable to patients requiring deep sedation. In the 
ﬁ rst 24  hours of the PRODEX trial, discontinuation of 
dexmedetomidine was more frequent because of a lack of 
eﬃ  cacy. As acknowledged by the authors of the PRODEX 
and MIDEX trials, most clini cians and centers do not 
consider dexmedetomidine an equivalent alternative to 
propofol and midazolam for long-term sedation. Th ese 
trials, nevertheless, reassure clinicians regarding the 
safety of dexmedetomidine in terms of higher doses over 
a long period of time.
Recent guidelines of the Society of Critical Care 
Medicine recommend using non-benzodiazepine agents, 
such as propofol or dexmedetomidine, over benzodia ze-
pines as a ﬁ rst-line sedative agent, and dexmedetomidine 
in patients at risk for delirium that is not related to 
alcohol and benzodiazepine use [11]. Th e opioid-sparing 
[11] eﬀ ect of dexmedetomidine may reduce opioid 
require ments in critically ill patients. Th e most common 
side eﬀ ects of dexmedetomidine are hypotension and 
bradycardia, and this limits its use in patients who are 
dependent on their cardiac output, such as patients in the 
acute phase of shock.
Recommendation
In carefully selected critically ill patients receiving 
prolonged mechanical ventilation, dexmedetomidine is 
safe and may be preferred as an alternative non-benzo-
diazepine agent to maintain light to moderate sedation. 
However, long-term outcomes, including neurocognitive 
eﬀ ects, and the safety of dexmedetomidine are unknown.
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